Zanzalintinib

Phase 3

Exelixis, Inc. (EXEL)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

EXELPhase 2$14.0B

Zanzalintinib Phase 2 Est. Readout (ZENOBIA)

Zanzalintinib• Head and Neck Squamous Cell Carcinoma40

Dec 2026~Estimated

CT.gov

00%

EXELPDUFA$14.0B

Phase 3

FDA PDUFA Date zanzalintinib

Zanzalintinib• patients with metastatic CRC who have been previously treated with fluoropyrimidine-

Dec 3Confirmed

SEC

00%

Competitive Landscape

3 competitors in Head and Neck Squamous Cell Carcinoma

MRUSPetosemtamab

Phase 3

MRUSInvestigator's Choice

Drug Information

Target Indication

Head and Neck Squamous Cell Carcinoma

Clinical Trial

NCT06082167

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

EXEL

Exelixis, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

XL184Phase 3

Glioblastoma Multiforme

XL092Phase 3

Non-Clear Cell Renal Cell Carcinoma

RegorafenibPhase 3

Colorectal Cancer

Cabozantinib tabletsPhase 3

Renal Cell Carcinoma

CabozantinibPhase 3

Solid Tumors

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts